

## Title (en)

METHOD FOR PR-39 PEPTIDE MEDIATED SELECTIVE INHIBITION OF IKAPPABALPHA DEGRADATION

## Title (de)

VERFAHREN ZUR HERSTELLUNG VON DURCH PR-39 PEPTID VERMITTELTE SELEKTIVER HEMMUNG VON IKAPPABALPHA ABBAU

## Title (fr)

PROCEDE D'INHIBITION SELECTIVE DE LA DEGRADATION DE LA PROTEINE IKAPPABALPHA INDUITE PAR LE PEPTIDE PR-39

## Publication

**EP 1242107 A4 20041006 (EN)**

## Application

**EP 00989492 A 20001227**

## Priority

- US 0035293 W 20001227
- US 47496799 A 19991229

## Abstract (en)

[origin: WO0147540A1] The present invention provides both a method and means for regulating I kappa B alpha degradation, NF kappa B activity, and NF kappa B-dependent gene expression within living cells, tissues, and organs in-situ. The selective regulation is performed using native PR-39 peptide or one of its shorter-length homologs, for interaction with such I kappa B alpha and proteasomes as are present in the cytoplasm of viable cells. The result of PR-39 peptide interaction with I kappa B alpha is a selective alteration in the intracellular proteolytic activity of proteasomes, which in turn, causes a reduction of I kappa B alpha, a decrease of NF kappa B activity, and a down-regulation of NF kappa B-dependent gene expression.

## IPC 1-7

**A61K 38/00**; **A61K 38/16**; **C07K 7/00**; **C07K 7/04**; **C07K 7/06**; **C07K 14/47**

## IPC 8 full level

**C07K 14/47** (2006.01); **A61K 38/00** (2006.01)

## CPC (source: EP)

**C07K 14/4705** (2013.01); **C07K 14/4723** (2013.01); **A61K 38/00** (2013.01)

## Citation (search report)

- [X] WO 9632129 A1 19961017 - UNIV KANSAS STATE [US], et al
- [X] WO 9835690 A1 19980820 - UNIV KANSAS STATE [US]
- [X] US 5489575 A 19960206 - LEE JONG-YOUN [SE], et al
- [PXL] WO 0057895 A1 20001005 - BETH ISRAEL HOSPITAL [US]
- [EL] WO 0130368 A1 20010503 - BETH ISRAEL HOSPITAL [US]
- [X] LI J ET AL: "CARDIAC-SPECIFIC OVEREXPRESSION OF PR-39 INDUCES ANGIOGENESIS, MYOCARDIAL HYPERTROPHY AND INCREASED MICROVASCULAR REACTIVITY", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 98, no. 17, October 1998 (1998-10-01), pages 1794, XP002929855, ISSN: 0009-7322
- [PX] GAO Y ET AL: "Inhibition of ubiquitin-proteasome pathway-mediated I-kappaBalpha degradation by a naturally occurring antibacterial peptide", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 106, no. 3, August 2000 (2000-08-01), pages 439 - 448, XP002180614, ISSN: 0021-9738
- [PX] HOFFMEYER M R ET AL: "PR-39, a potent neutrophil inhibitor, attenuates myocardial ischemia-reperfusion injury in mice.", AMERICAN JOURNAL OF PHYSIOLOGY. HEART AND CIRCULATORY PHYSIOLOGY. DEC 2000, vol. 279, no. 6, December 2000 (2000-12-01), pages H2824 - H2828, XP002292143, ISSN: 0363-6135
- [PA] LI J ET AL: "PR39, a peptide regulator of angiogenesis", NATURE MEDICINE, NATURE AMERICA, NEW YORK, US, vol. 6, no. 1, January 2000 (2000-01-01), pages 49 - 55, XP002968105, ISSN: 1078-8956
- [A] LI J ET AL: "Macrophage-dependent regulation of syndecan gene expression", CIRCULATION RESEARCH 1997 UNITED STATES, vol. 81, no. 5, 1997, pages 785 - 796, XP008033955, ISSN: 0009-7330
- [A] GAO YOUHE ET AL: "PR39 interacts with proteasome and modulates HIF-1alpha level in ECV cells", MOLECULAR BIOLOGY OF THE CELL, vol. 9, no. SUPPL., November 1998 (1998-11-01), & 38TH ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CELL BIOLOGY; SAN FRANCISCO, CALIFORNIA, USA; DECEMBER 12-16, 1998, pages 123A, XP008033931, ISSN: 1059-1524
- See references of WO 0147540A1

## Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

## DOCDB simple family (publication)

**WO 0147540 A1 20010705**; AU 2599001 A 20010709; CA 2397955 A1 20010705; EP 1242107 A1 20020925; EP 1242107 A4 20041006

## DOCDB simple family (application)

**US 0035293 W 20001227**; AU 2599001 A 20001227; CA 2397955 A 20001227; EP 00989492 A 20001227